Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Accumulated Expenses (2018 - 2026)

Immunovant filings provide 8 years of Accumulated Expenses readings, the most recent being $57.6 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 18.91% to $57.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.6 million through Dec 2025, up 18.91% year-over-year, with the annual reading at $51.1 million for FY2025, 23.77% up from the prior year.
  • Accumulated Expenses hit $57.6 million in Q4 2025 for Immunovant, up from $56.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $57.6 million in Q4 2025 and bottomed at $15.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $34.1 million, with a median of $31.8 million recorded in 2021.
  • The largest annual shift saw Accumulated Expenses soared 298.44% in 2021 before it decreased 17.16% in 2022.
  • Immunovant's Accumulated Expenses stood at $31.4 million in 2021, then fell by 17.16% to $26.0 million in 2022, then rose by 7.05% to $27.9 million in 2023, then soared by 73.84% to $48.5 million in 2024, then increased by 18.91% to $57.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Accumulated Expenses are $57.6 million (Q4 2025), $56.3 million (Q3 2025), and $45.1 million (Q2 2025).